Drug profile · INN
sotrovimab
XEVUDY
sotrovimab (XEVUDY) is a spike glycoprotein inhibitor.
EMA: withdrawn PMDA: approved Antiinfectives for systemic use (J06) J06BD05
Patents linked 0
Pipeline programs 6
News articles 0
Drug details — sotrovimab
- Class
- Antiinfectives for systemic use (J06)
- Route
- —
- Patents
- 0
- Programs
- 6
- Data quality
- 0.83
Quick answer
sotrovimab (XEVUDY) is a spike glycoprotein inhibitor.
Key facts
INN sotrovimab
Brand XEVUDY
Mechanism Spike glycoprotein inhibitor
Target Spike glycoprotein
Therapeutic class Antiinfectives for systemic use (J06)
ATC code J06BD05
Mechanism of action
Spike glycoprotein inhibitor
Primary target: Spike glycoprotein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is sotrovimab?
sotrovimab (XEVUDY) is a spike glycoprotein inhibitor.
What is the brand name for sotrovimab?
XEVUDY is a marketed brand name for sotrovimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.